167 related articles for article (PubMed ID: 19529911)
1. Reversal of refractory septic shock with drotrecogin alpha (activated).
Vieillard-Baron A; Caille V; Charron C; Belliard G; Aegerter P; Page B; Jardin F
Intensive Care Med; 2009 Jul; 35(7):1204-9. PubMed ID: 19529911
[TBL] [Abstract][Full Text] [Related]
2. Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.
Spapen H; Nguyen DN; Troubleyn J; Huyghens L; Schiettecatte J
Crit Care; 2010; 14(2):R54. PubMed ID: 20374626
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.
Póvoa P; Salluh JI; Martinez ML; Guillamat-Prats R; Gallup D; Al-Khalidi HR; Thompson BT; Ranieri VM; Artigas A
Crit Care; 2015 Apr; 19(1):193. PubMed ID: 25928214
[TBL] [Abstract][Full Text] [Related]
4. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
Dhainaut JF; Antonelli M; Wright P; Desachy A; Reignier J; Lavoue S; Charpentier J; Belger M; Cobas-Meyer M; Maier C; Mignini MA; Janes J
Intensive Care Med; 2009 Jul; 35(7):1187-95. PubMed ID: 19263034
[TBL] [Abstract][Full Text] [Related]
5. Drotrecogin alfa (activated) in adults with septic shock.
Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
[TBL] [Abstract][Full Text] [Related]
6. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.
Bilbault P; Lavaux T; Launoy A; Gaub MP; Meyer N; Oudet P; Pottecher T; Jaeger A; Schneider F
Crit Care Med; 2007 Jan; 35(1):69-75. PubMed ID: 17133181
[TBL] [Abstract][Full Text] [Related]
7. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
Bertolini G; Rossi C; Anghileri A; Livigni S; Addis A; Poole D
Intensive Care Med; 2007 Mar; 33(3):426-34. PubMed ID: 17325836
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C and septic shock: a propensity-matched cohort study*.
Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
[TBL] [Abstract][Full Text] [Related]
9. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
10. A dream deferred: the rise and fall of recombinant activated protein C.
Holder AL; Huang DT
Crit Care; 2013 Mar; 17(2):309. PubMed ID: 23509922
[TBL] [Abstract][Full Text] [Related]
11. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
[TBL] [Abstract][Full Text] [Related]
12. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
[TBL] [Abstract][Full Text] [Related]
14. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
[TBL] [Abstract][Full Text] [Related]
16. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
[TBL] [Abstract][Full Text] [Related]
17. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
18. Drotrecogin alpha (activated) in neonatal septic shock.
Frommhold D; Birle A; Linderkamp O; Zilow E; Pöschl J
Scand J Infect Dis; 2005; 37(4):306-8. PubMed ID: 15804668
[TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alpha (activated) in septic shock after lung transplant.
Feltracco P; Rea F; Ori C
J Heart Lung Transplant; 2008 Jul; 27(7):815. PubMed ID: 18582817
[No Abstract] [Full Text] [Related]
20. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
Crum NF; Groff HL; Parrish JS; Ring W
Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
